“…Specifically, we gavaged wild type mice with the viable cells of three bacterial strains representative of the taxonomic groups most commonly used as probiotics, including L. paracasei DG, a strain employed in commercial preparations available in Europe, America, and Asia, which has been demonstrated to efficiently survive the gastrointestinal (GI) transit in adult and pediatric populations ( Arioli et al, 2018 ; Radicioni et al, 2019 ), affect the gut microbiota taxonomic composition and butyrate levels in healthy adults and irritable bowel syndrome (IBS) patients ( Ferrario et al, 2014 ; Cremon et al, 2018 ), modulate the immune response in IBS and ulcerative colitis patients ( D’Inca et al, 2011 ; Cremon et al, 2018 ), and maintain remission of diverticular disease ( Tursi et al, 2008 , 2013 ). In addition, we tested Lactobacillus helveticus MIMLh5, a bacterial strain of dairy origin used in commercial paraprobiotic formulations available in Europe, which was shown in vitro to display antagonistic activity against pathogens and immunomodulatory properties on epithelial and antigen presenting cells ( Guglielmetti et al, 2010 ; Taverniti et al, 2012 , 2013 , 2019 ); in addition, MIMLh5 was shown during a clinical trial to contribute to the prevention of recurrent upper respiratory tract infections in adults and children with recurrent rhinopharyngitis ( Cavaliere et al, 2020 ). Finally, B. bifidum strain MIMBb23sg has been studied here as a representative member of its species, which possesses marked in vitro ability to efficiently adhere to Caco-2 enterocytes, utilize mucin as its sole carbon source, catabolize human milk oligosaccharides, and modulate cytokine expression in bone marrow derived dendritic cells and Caco-2 enterocytes.…”